Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTLaiba ImmadTue, June 30, 2026 at 3:22 PM GMT+2 2 min readWe recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list.TheFly reported on June 22 that Clear Street maintained its Buy rating and $70 price target on MLTX. The firm highlighted SLK's potential in hidradenitis suppurativa following the company's investor event focused on the therapy's development and commercialization strategy. Clear Street noted that SLK's profile in HS remains highly competitive and could support a significant commercial opportunity. The firm also stated that the Biologics License Application submission remains expected by September 30, with management continuing to view the possibility of priority review.MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis SuppurativaMoreover, on June 23, MoonLake Immunotherapeutics (NASDAQ:MLTX) announced the pricing of its underwritten public offering, including 9 million Class A ordinary shares at $20.00 per share and pre-funded warrants for up to 1 million additional shares at $19.9999 per warrant. The offering is expected to generate approximately $200 million in gross proceeds before fees and expenses. MLTX also provided underwriters with a 30-day option to purchase an additional 1.5 million Class A ordinary shares. The company plans to use the proceeds to support research, development, pre-commercialization, and commercialization activities for sonelokimab, if approved, and general corporate purposes.MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical-stage biopharmaceutical company developing innovative therapies for inflammatory skin and joint diseases, led by Sonelokimab, a next-generation IL-17 inhibitor.While we acknowledge the potential of MLTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info